Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR‐ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Shibata, Norihito, Miyamoto, Naoki, Nagai, Katsunori, Shimokawa, Kenichiro, Sameshima, Tomoya, Ohoka, Nobumichi, Hattori, Takayuki, Imaeda, Yasuhiro, Nara, Hiroshi, Cho, Nobuo, Naito, Mikihiko
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543464/
https://ncbi.nlm.nih.gov/pubmed/28556300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13284
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares